CD4 and neoplasm: Recent studies have demonstrated that HLA class II-restricted TCRs with high reactivity (avidity) to TAAs are also promising tools for the therapy because TAAs-reactive CD4+ T cells play essential roles in tumor eradication [8, 17, 18].